RALEIGH, N.C., Oct. 10, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its third quarter 2016 results after the market closes on Wednesday, November 2. The Company will [...]
See the latest interactions from our social media
On 10/31 Dr. Lynn Webster & Michael Marschler present a #webinar on Parmacogenetics & Pain Management. Register at the link.
Read the latest updates from our PR department
Takeda and PRA Health Sciences Announce Transformational Clinical Development and Marketed Product Partnership
Agreement Supports Accelerated, More Efficient Clinical Trial Strategy and Operations OSAKA, Japan & RALEIGH, N.C.--(BUSINESS WIRE)--PRA Health Sciences, Inc. (NASDAQ: PRAH) and Takeda Pharmaceutical [...]
$394.2 million of service revenue in the second quarter; 17.3% constant currency growth compared to the second quarter of 2015 Second quarter GAAP Net Income per diluted share increased 200.0% to $0.60 [...]
Explore the latest resources uploaded to our media library
Brought to you by PRA Health Sciences. A Bi-Weekly Industry Watch Newsletter
PRA recently performed a feasibility study to identify investigators who see patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial.
PRA Health Sciences provides our clients with innovative solutions for CNS (neurology, psychiatry, and pain) drug development. Our work spans from early phase development to NDA and MAA submissions...
A large pharmaceutical client selected PRA to conduct 2 Phase III epilepsy studies in India, Eastern and Western Europe, and Australia. PRA’s project teams surpassed recruitment goals and achieved timely site activations despite administrative delays and tough competition for volunteers.